DexCom (DXCM) director Heller sells 1,012 shares under 10b5-1 trading plan

Rhea-AI Filing Summary

DexCom director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on February 12, 2026 at $68.01 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this transaction, she beneficially owns 26,019 shares, including 5,046 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant date or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heller Bridgette P

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S		1,012(1)	D	$68.01	26,019(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 5,046 unvested restricted stock units which were granted on May 8, 2025 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Bridgette P. Heller	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DexCom (DXCM) director Bridgette Heller report?

DexCom director Bridgette P. Heller reported selling 1,012 shares of Common Stock in an open-market transaction at $68.01 per share on February 12, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025.

Was the DexCom (DXCM) insider sale by Bridgette Heller under a 10b5-1 plan?

Yes, the reported sale of 1,012 DexCom shares by director Bridgette P. Heller was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025. Such plans pre-schedule trades, helping separate them from short-term market or information timing decisions.

How many DexCom (DXCM) shares does Bridgette Heller own after this Form 4?

After the reported sale, Bridgette P. Heller beneficially owns 26,019 DexCom shares. This total includes 5,046 unvested restricted stock units granted on May 8, 2025, which are scheduled to vest based on time and the timing of DexCom’s 2026 Annual Meeting.

What price did DexCom (DXCM) director Bridgette Heller receive for the shares sold?

The reported transaction shows Bridgette P. Heller sold 1,012 DexCom Common Stock shares at a price of $68.01 per share. This reflects the execution price for the open-market sale conducted under her previously adopted Rule 10b5-1 trading plan.

What are the details of Bridgette Heller’s unvested DexCom (DXCM) restricted stock units?

Included in Bridgette P. Heller’s beneficial ownership are 5,046 unvested restricted stock units granted on May 8, 2025. These RSUs will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2026 Annual Meeting of Stockholders.

What role does Bridgette Heller hold at DexCom (DXCM)?

Bridgette P. Heller is identified as a director of DexCom, Inc. in the filing. She is not listed as an officer or 10% owner, and the Form 4 reflects her equity transactions and holdings in that board-level governance capacity.